

Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 328697 NRGBIOTIC

ARTG entry for Medicine Listed

Sponsor Natural Bio Pty Limited

Postal Address PO Box 384, MONA VALE, NSW, 1660

Australia

ARTG Start Date 16/01/2020
Product Category Medicine
Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. NRGBIOTIC

Product Type Single Medicine Product Effective Date 17/01/2023

Permitted Indications

Helps enhance/promote healthy muscle function

Enhance/promote energy levels

Support healthy emotional/mood balance

Maintain/support nervous system health

Aid/assist/helps synthesis of neurotransmitters

Helps reduce occurrence of symptoms of mild anxiety

Aid/assist/helps post exercise recovery

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must only refer to mild anxiety.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not take while on warfarin therapy without medical advice.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Page 1 of 2



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration

Oral

Visual Identification

Active Ingredients

Bifidobacterium bifidum 1 billion CFU
Lactobacillus acidophilus 2.5 billion CFU
magnesium orotate 400 mg
Equivalent: magnesium 25.5 mg

Streptococcus thermophilus

Other Ingredients (Excipients)

1.5 billion CFU 37.5 mg

ubidecarenone

colloidal anhydrous silica

disodium edetate gellan gum

hypromellose

magnesium stearate

maltodextrin

potable water

potassium acetate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.